Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 HBeAg Seroconversion and Loss by Pretreatment ALT Level

From: High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial

  HbeAg Seroconversion HBeAg Loss
ALT Level Number % Number %
<= 1 × ULN 0/10 - 3/10 30
>1-<=2 × ULN 6/20 30 10/20 50
>2-<=5 × ULN 11/20 55 14/20 70
> 5 × ULN 7/10 70 8/10 80
Total 24/60 40 35/60 58.3